Ingersoll Rand reports its Q2 results on July 31 with the borrow market calmer than it has been all year and short sellers quietly covering — but analysts remain split on whether the margin story has turned a corner.
Short interest has fallen roughly 6% over the past month and another 6% on the week, now running at 3.8% of the free float. That retreat is meaningful: bears were carrying closer to 4.1% of float just days ago, and the covering accelerated noticeably around July 23. Borrow conditions confirm there is no squeeze pressure. Availability has tightened slightly to 913% from above 1,000% the week prior — still extraordinarily loose, meaning shares available to borrow vastly outnumber those already shorted. The cost to borrow has eased to 0.52%, close to its lowest level of the past month. Options positioning echoes the same relaxed tone. The put/call ratio is 0.22, fractionally below its 20-day average and near the bottom of its 52-week range — a call-heavy stance that reflects little demand for downside protection heading into the print.
The central debate is whether IR can demonstrate that margin pressure from last quarter was temporary. The bear case has teeth: the company trimmed its 2025 organic sales guidance last quarter, citing lower tariff-related pricing, and adjusted EBITDA margins slipped 40 basis points year-on-year to 27%. Analysts have been trimming targets steadily since early April, and Stifel moved its target down to $84 — essentially the current price — as recently as July 20, maintaining a Hold. The consensus price target sits at $93.64, implying about 11% upside from the current $84.32, but the direction of travel has been one-way. Bulls point to a 16% backlog increase, a book-to-bill ratio above 1x, and strong order growth in the Americas and APAC as evidence that end demand remains firm. Citi holds a Buy with a $109 target; Barclays and Wells Fargo are Overweight at $95 and $88 respectively — both above the current price but well below their pre-April levels.
The earnings report will test whether organic volume growth can offset the pricing headwinds that forced guidance lower — and whether the EBITDA margin line is recovering toward the 29%-plus level it held a year ago, or settling into a structurally lower band.
See the live data behind this article on ORTEX.
Open IR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
